Competitive Landscape Novo Nordisk and Eli Lilly jointly command a major share of the Latin America GLP-1 agonists market through semaglutide, dulaglutide, and tirzepatide portfolios
Regular evaluation of HbA1c, body weight, and cardiovascular parameters enables early detection of inadequate response or emerging risks
In Phase II trials: Efinopegdutide (Merck/Johnson & Johnson/Hanmi Harma), VK2735 (Viking Therapeutics), BGM0504 (BrightGene), Pemvidutide (Altimmune/Spitfire Pharma), AMG133 (Amgen), Dapiglutide (Zealand Pharma), etc
359 Side-sleeping appears to promote better cleansing of brain tissue through increased glymphatic drainage
Any references to biological systems are included solely for academic context and do not constitute therapeutic, diagnostic, or clinical claims